利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

777 条记录 (耗时 0.028 秒)

    MUTANT PROTEIN
    32.
    发明公开
    MUTANT PROTEIN 审中-公开
    突变蛋白

    公开(公告)号：EP3249047A3

    公开(公告)日：2018-02-28

    申请号：EP17166519.3

    申请日：2003-03-20

    申请人： GE Healthcare BioProcess R&D AB

    发明人： HOBER, Sophia

    IPC分类号： C12N15/31 ,  C07K14/31 ,  C07K1/22 ,  B01D15/08 ,  B01D15/38 ,  B01J20/24 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32 ,  C07K16/06

    摘要： The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylo-coccal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

    摘要翻译： 本发明涉及免疫球蛋白结合蛋白，其中至少一个天冬酰胺残基已经突变为除谷氨酰胺或天冬氨酸以外的氨基酸，该突变在pH值高达约13-14时赋予增加的化学稳定性 到亲代分子。 蛋白质可以例如衍生自能够结合免疫球蛋白分子的其他区域的蛋白质，而不是互补决定区（CDR），例如蛋白质A，并且优选地是葡萄球菌 - 可可蛋白质A的B结构域。本发明还可以 涉及用于亲和分离的基质，其包含与固体支持物偶联的作为配体的免疫球蛋白结合蛋白，其中蛋白质配体中至少一个天冬酰胺残基已经突变为非谷氨酰胺的氨基酸。

    MUTANT PROTEIN
    33.
    发明公开
    MUTANT PROTEIN 审中-公开

    公开(公告)号：EP3249047A2

    公开(公告)日：2017-11-29

    申请号：EP17166519.3

    申请日：2003-03-20

    申请人： GE Healthcare BioProcess R&D AB

    发明人： HOBER, Sophia

    IPC分类号： C12N15/31 ,  C07K14/31 ,  C07K1/22 ,  B01D15/08 ,  B01D15/38 ,  B01J20/24 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32 ,  C07K16/06

    摘要： The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylo-coccal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

    VACCINE COMPRISING MONOCYTE OR IMMATURE MYELOID CELLS(IMC) WHICH WERE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN
    35.
    发明授权
    VACCINE COMPRISING MONOCYTE OR IMMATURE MYELOID CELLS(IMC) WHICH WERE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN 有权
    含有天然杀伤T细胞和抗原配体的单核细胞或未成熟的髓细胞（IMC）疫苗

    公开(公告)号：EP2227253B1

    公开(公告)日：2017-05-17

    申请号：EP07834349.8

    申请日：2007-11-28

    申请人： Cellid Co., Ltd

    发明人： KANG, Chang-Yuil ,  KO, Hyun-Jeong ,  LEE, Jung-Mi ,  KIM, Yeon-Jeong

    IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K48/00 ,  C07K14/31 ,  C07K14/715 ,  C07K16/32 ,  C12N5/07

    CPC分类号： C07K16/32 ,  A61K31/164 ,  A61K39/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0645 ,  C12N2501/999 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/476

    摘要： The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

    摘要翻译： 本发明涉及免疫治疗和预防性疫苗，其包含负载天然杀伤T细胞配体的单核细胞或未成熟骨髓细胞（IMC）和用于预防和治疗感染性疾病或癌症的抗原，更准确地说， 包含负载α-半乳糖苷神经酰胺（αGalCer），一种糖脂和天然杀伤T细胞配体的单核细胞或IMC以及抗原的治疗性和预防性疫苗。 与树突细胞不同，易于获得的单核细胞或未成熟骨髓细胞（IMC）不仅诱导显着水平的细胞毒性T淋巴细胞反应，而且对恶性肿瘤具有预防和治疗作用。 因此，本发明的免疫治疗和预防性疫苗可以有效地用作免疫治疗剂。